atech system solutions Develops New Bioreactor Platform for Cell Culture-Based Manufacturing
The atech system solutions Ltd. presents a new generation of bioreactor systems for cell culture-based manufacturing of biopharmaceutical compounds. The new development comprises a platform technology with high performance, safety as well as environmental compatibility and simplification of cell culture-based manufacturing methods. The system platform will be marketed under the brand name “cellexis one.”
“The system cellexis one simplifies the entire bioprocess,” explains Dr. Sohéil Asgari, atech’s Chief Technology Officer. “Our design objective was to combine the best of suspension cultivation with the advantages of adherent cell cultivation. The result is impressive, because with the technology of cellexis one we reduce costs in production infrastructure, the operational cost and complexity of biotechnological cell culture methods.” Thereby, with a single system of cellexis one, up to 150 conventional systems could be replaced. The quantitative increase in productivity does not concern the efficiency only, but also simplifying the process itself.
"atech has resolved the basic problem of adherent cell cultivation, namely the limitations of cell culture by the surface area available for inoculation and subsequently the maximum cell density of adherent cell cultures at given surface areas. Our new bioreactor systems enable through the specific bioreactor design the decoupling of cell numbers at inoculation from the actual total surface area that is available for adherent cell growth in the bioreactor,” adds Dr. Sohéil Asgari. For the first time it is now feasible to continuously cultivate and produce cell cultures and cell culture products in one single system without the otherwise periodic detachment and redistribution of cell cultures into multiple cultivation systems.
atech plans to market the system of bioreactor systems as a product family of various sized bioreactor types, whose fundamental design is identical. The smallest bioreactor type will comprise an effective volume of aprox. 17ml providing an effective growth surface of 2300cm2, the largest an effective volume of approc. 44oml with an effective growth surface of approx. 115000cm2; between those two sizes additional two or three systems may be offered. The cellexis one systems can be entirely combined with other components like pumps for media circulation, systems for gas exchange or monitoring. The global sales and distribution of the systems by atech is expected to begin by beginning of October 2011.
About atech system solutions Ltd.
atech system solutions develops and markets technologies and technology services for creating and securing of technology-based assets. atech designs, developed and supplies new or existing product technologies, business models and business processes for small and medium enterprises (SMEs).
atech combines the range of services in three business areas: (i) consulting services (see http://www.atech-partners.com/consulting) for strategic consulting services in connection with technology strategy, business processes and M & A, (ii) Technology (see http://www.atech-partners.com/technology) for technology services such as contract R&D, design of quality systems, technology marketing and information services and (iii) Operations (see http://www.atech-partners.com/operations) for services in connection with operational R&D, quality and distribution processes.
atech system solutions Ltd.
Mainzer Str. 10
Tel. +49 (0)611 - 172 77 55 30
Dr. Sohéil Asgari
+49 611 172 77 55 30